Candel Therapeutics Files 8-K on Financials and Operations
Ticker: CADL · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1841387
Sentiment: neutral
Topics: financial-condition, operations, regulation-fd
TL;DR
Candel Therapeutics dropped an 8-K on Jan 13, 2025, covering financials and operations. Check it out.
AI Summary
Candel Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes disclosures under Regulation FD and other events, along with financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Needham, MA.
Why It Matters
This 8-K filing provides investors with crucial updates on Candel Therapeutics' financial health and operational status, impacting investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant financial and operational updates that may impact a company's stock price.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Needham, MA (location) — Principal Executive Offices
- 001-40629 (other) — SEC File Number
FAQ
What specific financial information is being disclosed in this 8-K filing?
This 8-K filing pertains to Candel Therapeutics, Inc.'s results of operations and financial condition, and includes financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on January 13, 2025.
What is the principal executive office address for Candel Therapeutics, Inc.?
The principal executive offices of Candel Therapeutics, Inc. are located at 117 Kendrick St., Suite 450, Needham, MA 02494.
What is the SEC file number for Candel Therapeutics, Inc.?
The SEC file number for Candel Therapeutics, Inc. is 001-40629.
Under which sections of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 676 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2025-01-13 08:05:35
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share CADL The Nasdaq
- $102.9 million — d cash position at December 31, 2024 of $102.9 million. A copy of the full press release is
Filing Documents
- cadl-20250113.htm (8-K) — 49KB
- cadl-ex99_1.htm (EX-99.1) — 61KB
- img160460863_0.jpg (GRAPHIC) — 32KB
- 0000950170-25-004581.txt ( ) — 283KB
- cadl-20250113.xsd (EX-101.SCH) — 27KB
- cadl-20250113_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. The information contained in Item 8.01 of this Current Report on Form 8-K, to the extent required, is incorporated into this Item 2.02 by reference.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 13, 2025, Candel Therapeutics, Inc. (the "Company") issued a press release providing a corporate update, which highlighted the strong pipeline momentum from 2024 and upcoming key value drivers for 2025 and announced its unaudited cash position at December 31, 2024 of $102.9 million. A copy of the full press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.
01 Other Events
Item 8.01 Other Events. On January 13, 2025, the Company announced that its unaudited cash position at December 31, 2024 was $102.9 million. This amount is unaudited and preliminary and is subject to the completion of financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company's financial statements as of and for the year ended December 31, 2024.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Candel Therapeutics, Inc. Date: January 13, 2025 By: /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer